guaifenesin and pseudoephedrine hydrochloride · GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 · Tablet, Multilayer, Extended Release · Oral · Rugby Laboratories
NDC 00536-1449-36 · 2 BLISTER PACK in 1 CARTON / 18 TABLET, MULTILAYER, EXTENDED RELEASE in 1 BLISTER PACK · ANDA · View full market →
11 companies supply this market — deep enough that no single failure threatens the supply. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
price up 24% YoY · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Cardinal Health 110, LLC. dba Leader | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Cvs Woonsocket Prescription Center, Incorporated | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| H E B | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Kroger Company | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| L. Perrigo Company | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Meijer, Inc. | GUAIFENESIN 1200 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 120 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Meijer, Inc. | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Rugby Laboratories | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Strategic Sourcing Services LLC | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Topco Associates LLC | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Walgreen Company | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Walmart Inc. | GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Rugby Mucus Relief D — NDC 00536-1449-36," retrieved September 3, 2026, https://drugdashboards.com/drug/00536144936.
Free to cite with attribution — see how the data is put together.